Antiplatelet and Anticoagulation    The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease Heart, 2010. 96(5): p. 368-71. M. Wurtz, et al., Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP Am Heart J, 2010. 159(3): p. 434-8. C. M. Moerenhout, et al., Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database Am Heart J, 2010. 159(3): p. 462-470 e1. J. L. Petersen, et al., Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Circulation, 2010. 121(1): p. 71-9. E. M. Mahoney, et al., Factor XIIa Inhibitor Recombinant Human Albumin Infestin-4 Abolishes Occlusive Arterial Thrombus Formation Without Affecting Bleeding Circulation, 2010. I. Hagedorn, et al., Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events Am Heart J, 2010. 159(3): p. 361-369 e4. T. Teramoto, et al., Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience Am Heart J, 2010. 159(2): p. 190-8. F. Schiele, et al., ST segment resolution in patients with tenecteplase-facilitated percutaneous coronary intervention versus tenecteplase alone: Insights from the Combined Angioplasty and Pharmacological Intervention versus Thrombolysis ALone in Acute Myocardial Infarction (CAPITAL AMI) trial Can J Cardiol, 2010. 26(1): p. e7-12. D. Y. So, et al., Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry) Am Heart J, 2010. 159(2): p. 284-291 e1. S. W. Lee, et al., Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation, 2009. 119(22): p. 2877-85. J. H. Alexander, et al.,